AGP
SRPT icon

Artia Global Partners’s Sarepta Therapeutics SRPT Stock Holding History

Artia Global Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60,000
Closed -$8.27M – 42
2023
Q1 		$8.27M Buy
+60,000
New +$7.78M 3.06% 12

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Artia Global Partners's SRPT Position: Q4 2025 in Review

Artia Global Partners sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 44,900 shares — an estimated $865K sold.

Artia Global Partners first reported a position in SRPT in Q2 2023 and held it in 4 quarters. The position peaked at $8.84M in Q2 2023. 344 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Artia Global Partners reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Artia Global Partners sold 44,900 Sarepta Therapeutics shares in Q4 2025, an estimated $865K.
  • Artia Global Partners first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 4 quarters.
  • Artia Global Partners's Sarepta Therapeutics position peaked at $8.84M in Q2 2023.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.